Skip to main content
SpringerLink
Log in

Therapeutic potential of blockade of the Urotensin II system in systemic hypertension

  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Urotensin II, an 11-amino acid peptide, has been found to be the most potent vasoconstrictor yet described, in certain vascular beds. Discovery of its endogenous receptor (UII-R) has ignited considerable interest in this system’s role in disease states associated with increased vascular tone (eg, systemic hypertension). Urotensin II was shown to have direct effects on the heart in addition to effects on vascular tone. In human systemic hypertension, increased plasma levels of urotensin II were noted, with a weak but significant correlation to absolute blood pressure levels. Furthermore, hypertensive patients demonstrate net vasoconstrictor responsiveness in skin microcirculation compared to normal controls. Highly selective UII-R antagonists have been developed based on the known structure of UII-R. Early preclinical and clinical studies report potential beneficial effects in renal disease, heart failure, and diabetes, although effects on blood pressure have been equivocal.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Bern H, Pearson D, Larson B, Nishioka R: Complete amino acid sequence of urotensin I, a hypotensive and corticotropin-releasing neuropeptide from Catostomus. Recent Prog Horm Res 1985, 41:533–552.

    PubMed  CAS  Google Scholar 

  2. Elshoubagy N, Douglas S, Shabon U, et al.: Molecular and pharmacological characteristics of genes encoding urotensin II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br J Pharmacol 2002, 136:9–22.

    Article  Google Scholar 

  3. Coulouarn Y, Jegou S, Tostivint H, et al.: Cloning, sequence analysis and tissue distribution of the mouse and rat urotensin II precursors. FEBS Lett 1999, 457:28–32.

    Article  PubMed  CAS  Google Scholar 

  4. Pearson D, Shively J, Clark B, et al.: Urotensin II: a somatostatin-like peptide in the caudal neurosectretory system of fishes. Proc Natl Acad Sci U S A 1980, 77:5021–5024.

    Article  PubMed  CAS  Google Scholar 

  5. Krum H, Kompa A, Hannan R, Thomas W: Emerging role of the urotensin II system in cardiovascular disease. Heart Drug 2003, 3:153–158.

    Article  CAS  Google Scholar 

  6. Carotenuto A, Grieco P, Campiglia P, et al.: Unraveling the active confirmation of urotensin II. J Med Chem 2004, 47:1652–1661.

    Article  PubMed  CAS  Google Scholar 

  7. Bern H, Pearson D, Larson B, Nishioka R: Neurohormones from fish tails: the caudal neurosecretory system. I. “Urophysiology” and the caudal neurosecretory system of fishes. Recent Prog Hormone Res 1995, 41:533–552.

    Google Scholar 

  8. Douglas S, Dhanak D, Johns D: From ‘gills to pills’: urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci 2004, 25:76–85.

    Article  PubMed  CAS  Google Scholar 

  9. Flohr S, Kurtz M, Kostenis E, et al.: Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J Med Chem 2002, 45:1799–1805.

    Article  PubMed  CAS  Google Scholar 

  10. Wilson S, Bergsma D, Chambers J, et al.: Orphan G-protein-coupled receptors: the next generation of drug targets?. Br J Pharmacol 1998, 125:1387–1392.

    Article  PubMed  CAS  Google Scholar 

  11. Liu Q, Pong SS, Zeng Z, et al.: Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem Biophys Res Commun 1999, 266:174–178.

    Article  PubMed  CAS  Google Scholar 

  12. Maguire J, Davenport A. Is urotensin II the new endothelin?. Br J Pharmacol 2002, 137:579–588.

    Article  PubMed  CAS  Google Scholar 

  13. Sauzeau V, Mellionnec E, Bertoglio J, et al.: Human urotensin II induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-Kinase. Circ Res 2001, 88:1102–1104.

    PubMed  CAS  Google Scholar 

  14. Mori M, Sugo T, Abe M, et al.: Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). Biochem Biophys Res Comm 1999, 265:123–129.

    Article  PubMed  CAS  Google Scholar 

  15. Totsune K, Takahashi K, Arihara Z, et al.: Role of urotensin II in patients on dialysis. Lancet 2001, 358:810–811.

    Article  PubMed  CAS  Google Scholar 

  16. Ames RS, Sarau HM, Chambers JK, et al.: Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999, 401:282–286.

    Article  PubMed  CAS  Google Scholar 

  17. Behm D, Harrison S, Ao Z, et al.: Deletion of the UT receptor gene results in the selective loss of urotensin II contractile activity in the aortae isolated from UT receptor knockout mice. Br J Pharmacol 2003, 139:464–472.

    Article  PubMed  CAS  Google Scholar 

  18. Stirrat A, Gallagher M, Douglas S, et al.: Potent vasodilatory responses to human urotensin II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol 2001, 280:H925–H928.

    PubMed  CAS  Google Scholar 

  19. Hillier C, Berry C, Petrie M, et al.: Effects of urotensin II in human arteries and veins of varying calibre. Circulation 2001, 103:1378–1381.

    PubMed  CAS  Google Scholar 

  20. Maguire J, Kuc R, Davenport A: Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasconstrictor responses with endothelin-1. Br J Pharmacol 2000, 131:441–446.

    Article  PubMed  CAS  Google Scholar 

  21. Russell F, Molenaar P, O’Brien D: Cardiostimulant effects of urotenin II in human heart in vitro. Br J Pharmacol 2001, 132:5–9.

    Article  PubMed  CAS  Google Scholar 

  22. Douglas S, Sulpizio A, Piercy V, et al.: Differential vasoconstrictor activity of human urotensin II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 2000, 131:1262–1274.

    Article  PubMed  CAS  Google Scholar 

  23. Gardiner S, March J, Kemp P, et al.: Depressor and regionally selective vasodilator effects of human and rat urotensin II in conscious rats. Br J Pharmacol 2001, 132:1625–1629.

    Article  PubMed  CAS  Google Scholar 

  24. Lin Y, Tsuchihashi T, Matsumura K, et al.: Central cardiovascular action of urotensin II in conscious rats. J Hypertens 2003, 21:159–165.

    Article  PubMed  CAS  Google Scholar 

  25. Wilkinson I, Affolter J, de Haas S, et al.: High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc Res 2002, 53:341–347.

    Article  PubMed  CAS  Google Scholar 

  26. Affolter J, Newby D, Wilkinson I, et al.: No effect on central or peripheral blood pressure or systemic urotensin II infusion in humans. Br J Clin Pharmacol 2002, 54:617–621.

    Article  PubMed  CAS  Google Scholar 

  27. Bohm F, Pernow J: Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 2002, 135:25–27.

    Article  PubMed  CAS  Google Scholar 

  28. Douglas S: Human urotensin II as a novel cardiovascular target: ‘heart’ of the matter or simply a fishy ‘tail’?. Curr Opin Pharmacol 2003, 3:159–167.

    Article  PubMed  CAS  Google Scholar 

  29. Lim M, Honisett S, Sparkes C, et al.: Differential effect of urotensin II on vascular tone in normal subjects and patients with chronic heart failure. Circulation 2004, 109:1212–1214.

    Article  PubMed  CAS  Google Scholar 

  30. Abdelrahman A, Pang C: Involvement of the nitric oxide/L-arginine and sympathetic nervous systems on the vasodepressor action of human urotensin II in anesthetized rats. Life Sci 2002, 71:819–825.

    Article  PubMed  CAS  Google Scholar 

  31. Zhang A, Chen Y, Zhang D, et al.: Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol 2003, 285:F792–F798.

    PubMed  CAS  Google Scholar 

  32. Cheung B, Leung R, Bun Man Y, Wong L: Plasma concentration of urotensin II is raised in hypertension. J Hypertens 2004, 22:1341–1344.

    Article  PubMed  CAS  Google Scholar 

  33. Matsushita M, Shichiri M, Imai T, et al.: Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissue. J Hypertens 2001, 19:2185–2190.

    Article  PubMed  CAS  Google Scholar 

  34. Sondermeijer B, Kompa A, Komesaroff P, Krum H: Effect of exogenous urotensin-II on vascular tone in skin micro-circulation of patients with essential hypertension. Am J Hypertens 2005, 18:1195–1199.

    Article  PubMed  CAS  Google Scholar 

  35. Watanabe T, Pakala R, Katagiri T, Benedict C: Synergistc effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. J Hypertens 2001, 19:2191–2196.

    Article  PubMed  CAS  Google Scholar 

  36. Russell F, Molenaar P: Cardiovascular actions of human urotensin II—considerations for hypertension. Naunyn Schmiedebergs Arch Pharmacol 2004, 369:274–280.

    Article  Google Scholar 

  37. Totsune K, Takahashi K, Arihara Z, et al.: Role of urotensin II in patients on dialysis. Lancet 2001, 358:810–811.

    Article  PubMed  CAS  Google Scholar 

  38. Langham R, Kelly DJ, Gow RM, et al.: Increased expression of urotensin II and urotensin receptor in human diabetic nephropathy. Am J Kidney Dis 2004, 44:826–831.

    Article  PubMed  CAS  Google Scholar 

  39. Tzanidis A, Hannan RD, Thomas WG, et al.: Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 2003, 93:246–253.

    Article  PubMed  CAS  Google Scholar 

  40. Ng L, Loke I, O’Brien R, et al.: Plasma urotensin in human systolic heart failure. Circulation 2002, 106:2877–2880.

    Article  PubMed  CAS  Google Scholar 

  41. Richards A, Nicholls M, Lainchbury J, et al.: Plasma urotensin II in heart failure. Lancet 2002, 360:545–546.

    Article  PubMed  CAS  Google Scholar 

  42. Russell F, Meyers D, Galbraith A, et al.: Elevated plasma levels of human urotensin II immunoreactivity in congestive heart failure. Am J Physiol Heart Circ Physiol 2003, 285:H1576–H1581.

    PubMed  CAS  Google Scholar 

  43. Douglas S, Tayara L, Ohlstein E, et al.: Congestive heart failure and expression of myocardial urotensin II. Lancet 2002, 359:1990–1997.

    Article  PubMed  CAS  Google Scholar 

  44. Behm D, Herold C, Ohlstein E, et al.: Pharmacological characterisation of SB-7104011 (Cpa-c/D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin II receptor antagonist. Br J Pharmacol 2002, 137:449–458.

    Article  PubMed  CAS  Google Scholar 

  45. Camarda V, Guerrini R, Kostenis E, et al.: A new ligand for the urotensin II receptor. Br J Pharmacol 2002, 137:311–314.

    Article  PubMed  CAS  Google Scholar 

  46. Herold C, Behm D, Buckles P, et al.: The neuromedin B receptor antagonist BIM-23127 is a potent antagonist at human and rat urotensin II receptors. Br J Pharmacol 2003, 139:203–207.

    Article  PubMed  CAS  Google Scholar 

  47. Clozel M, Binkert C, Birker-Robaczewska M, et al.: Pharmacology of the urotensin II receptor antagonist ACT-058362: first demonstration of a pathophysiological role of the urotensin system. J Pharmacol Exp Ther 2004, 311:204–212.

    Article  PubMed  CAS  Google Scholar 

  48. Sidharta PN, Wagner FD, Bohnemeier H, et al.: Pharmacodynamics and pharmacokinetics of the urotensin II receptor antagonist palosuran in macroalbuminuric, diabetic patients. Clin Pharmacol Ther 2006, 80:246–256.

    Article  PubMed  CAS  Google Scholar 

  49. Bousette N, Hu F, Ohlstein EH, et al.: Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. J Mol Cell Cardiol 2006, 41:285–295.

    Article  PubMed  CAS  Google Scholar 

  50. Palosuran in Clinical Development. Available at: http://www.actelion.com/uninet/www/www_main_p.nsf/Content/Other+Projects+in+Clinical+Development.

Download references

Author information

Authors and Affiliations

  1. Department of Epidemiology and Preventive Medicine, Monash University/Alfred Hospital, 89 Commercial Road, Melbourne, VIC, 3004, Australia

    Henry Krum MBBS, PhD, FRACP, FCSANZ

Authors
  1. Henry Krum MBBS, PhD, FRACP, FCSANZ
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Will Kemp MBBS, FRACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Henry Krum MBBS, PhD, FRACP, FCSANZ.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krum, H., Kemp, W. Therapeutic potential of blockade of the Urotensin II system in systemic hypertension. Current Science Inc 9, 53–58 (2007). https://doi.org/10.1007/s11906-007-0010-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-007-0010-x

Keywords

Search

Navigation